scholarly journals Downregulation of vascular endothelial growth factor receptor-2 under oxidative stress conditions is mediated by β-transduction repeat-containing protein via glycogen synthase kinase-3β signaling

2016 ◽  
Vol 37 (4) ◽  
pp. 911-920 ◽  
Author(s):  
WEN WU ◽  
DAIMIN ZHANG ◽  
DAORONG PAN ◽  
GUANGFENG ZUO ◽  
XIAOMIN REN ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Glycogen Synthase ◽  
Growth Factor Receptor ◽  
Stress Conditions ◽  
Glycogen Synthase Kinase ◽  
Vascular Endothelial ◽  
Glycogen Synthase Kinase 3Β ◽  
Endothelial Growth Factor

Fortgeschrittenes medulläres Schilddrüsenkarzinom: Vandetanib verbessert das progressionsfreie Überleben

2012 ◽  
Vol 03 (02) ◽  
pp. 93-92
Author(s):  
Alexander Kretzschmar
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Phase Iii ◽  
Vascular Endothelial ◽  
Medulläres Schilddrüsenkarzinom ◽  
Epidermal Growth ◽  
Endothelial Growth Factor

Vandetanib ist ein oraler Hemmer des RET-Kinase-, VEGF (Vascular Endothelial Growth Factor Receptor)- und EGFR (Epidermal Growth Factor Receptor)-Signalwegs. In einer zulassungsrelevanten, randomisierten, doppelblinden, placebokontrollierten Phase- III-Studie verlängerte der Tyrosinkinasehemmer das progressionsfreie Überleben (PFS) signifikant länger als Placebo.

Sign in / Sign up

Export Citation Format

Share Document